WE BELIEVE IN FACT-BASED DECISION MAKING AND STRONG METHODOLOGY
Investing in a start-up with attractive upside potentials means that an investor must rely on a rare combination of few facts about its current and near horizon expected developments complemented with a more visionary future. As an angel powered fund, we like to make rational decisions based on facts. In the near horizon the focus is on avoiding downside value inflection points, while in the longer horizon the conquering of the upsides take over.
The final assessment of facts and visions rests on multiple perspectives of our experienced angels and general partners. We pride ourselves in employing methodologies based on solid research on Best Market Practices of high-yielding Silicon Valley venture funds as well as on experience based analytical methods tested in previous Stoaf funds. Our core team of General Partners and Certified Business Angels help us identify upsides and downsides of a variety of start-ups within SciTech´s four selected investment. And it supports our competence inputs in the start-ups we select.
SELECTION & INVESTMENT
High Deal Flow (~500 ventures/year)
High Accuracy Four-step Selection Process
Thourough Due Diligence
Optimized Investment Design
Fair Deal Design
Seniority and Experience
Active Board Participation
Reaching Upside Value Inflection Points
Steer Clear of Downside Inflection Points
Specialist also in Mid-stage Development
Optimizing Successful Exits
IPO, Trade Sell and M&A
EDUCATION AND CERTIFICATION
Angels investing in SciTech come with a variety of educational, professional and personality backgrounds. And they have different languages and communication skills. For this reason, Stoaf provides a 3-step education and case training to make them better adapted to a variety of tasks they chose to do.
THE CASE: BIO-WORKS
Bio-Works carries out R&D, manufacturing and supply of agarose-based resins used to separate proteins and other biomolecules. In this large and well-established area, their products stand out as innovative and cutting edge with exceptional performance.
THE CASE: ADDBIO
AddBio is revolutionizing the implant industry by solving a worldwide health problem – inadequate bone holding power.Zolidd® strengthens the bone, and significantly improved implant performance has been proven in a clinical study.
THE CASE: ISAB
Inhalation Sciences’ primary product PreciseInhale is an advanced laboratory system that lets scientists measure how inhaled particles act in our lungs and affect our health.